pancreatic cancer, pain, opioids, analgesic therapy, celiac plexus neurolysis, endosonography pancreascarcinoom, morfine, analgetica, plexus coeliacus blokkade, endo-echo
Conditions
Interventions
Patients will be randomised according to two treatment algorithms. The first “conventional” type treatment algorithms consists of increasing dosages of transdermal fentanyl patches. In this algorithm,
Sponsors
A.Voorburg
MD, gastroenterologist.
Academical Medical Center Amsterdam
The Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: 1. Cytological or histological proven irresectable pancreatic carcinoma; 2. Chronic pain unresponsive to non-opioid analgesic drugs and low dose fentanyl (Durogesic®) transdermal patches (VAS score >3 (figure 2)while using fentanyl transdermal patches maximum 50 ìg/h, 1 patch per 3 days); 3. Age above 18 years; 4. Karnovsky score >30 % (see table3)
Exclusion criteria
Exclusion criteria: 1. Previous celiac plexus blockade; 2. Use of opioids; 3. Refusal to sign informed co
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quality of Adjusted Life Years (QALYs) will be the primary outcome parameter. This is a composite endpoint linking survival and quality of life, i.e. the number of quality adjusted life years. These are based on biweekly assessments of health status with the EQ-5D questionnaire. The utility of each observed health score profile on the EQ-5D will be derived from previous research in which the time trade off based elicitation technique during interviews with adults from the general population has been applied. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Health-related quality of life (EORTC-QLQ-C30)(see table 2) 2. Survival 3. Opioid requirement 4. Health status (EQ-5D)(table 1 and figure 3) 5. Adverse effects 6. Costs | — |
Contacts
Public ContactA. M.C.J. Voorburg
Outcome results
None listed